Isolation and Characterization of Two Novel Colorectal Cancer Cell Lines, Containing a Subpopulation with Potential Stem-Like Properties: Treatment Options by MYC/NMYC Inhibition by Schulte am Esch, Jan et al.
cancers
Article
Isolation and Characterization of Two Novel
Colorectal Cancer Cell Lines, Containing
a Subpopulation with Potential Stem-Like Properties:
Treatment Options by MYC/NMYC Inhibition
Jan Schulte am Esch 1,2,†, Beatrice Ariane Windmöller 2,3,*,† , Johannes Hanewinkel 3,
Jonathan Storm 2,3, Christine Förster 2,4, Ludwig Wilkens 2,4, Martin Krüger 2,5,
Barbara Kaltschmidt 2,3,6,‡ and Christian Kaltschmidt 2,3,‡
1 Department of General and Visceral Surgery, Protestant Hospital of Bethel Foundation, 33611 Bielefeld,
Germany; Jan.SchulteamEsch@evkb.de
2 Forschungsverbund BioMedizin Bielefeld (FBMB), 33611 Bielefeld, Germany;
jonathan.storm@uni-bielefeld.de (J.S.); christine.foerster@krh.eu (C.F.); ludwig.wilkens@krh.eu (L.W.);
Martin.Krueger@evkb.de (M.K.); barbara.kaltschmidt@uni-bielefeld.de (B.K.);
C.Kaltschmidt@uni-bielefeld.de (C.K.)
3 Department of Cell Biology, University of Bielefeld, 33611 Bielefeld, Germany;
johannes-hanewinkel@hotmail.de
4 Institute of Pathology, KRH Hospital Nordstadt, affiliated with the Protestant Hospital of Bethel Foundation,
30167 Hannover, Germany
5 Department of Internal Medicine and Gastroenterology, Protestant Hospital of Bethel Foundation,
33611 Bielefeld, Germany
6 Molecular Neurobiology, University of Bielefeld, 33615 Bielefeld, Germany
* Correspondence: beatrice.windmoeller@uni-bielefeld.de; Tel.: +49-0521-106-5629
† These authors contributed equally as Co-First authors.
‡ These authors contributed equally as Co-Last authors.
Received: 14 August 2020; Accepted: 8 September 2020; Published: 10 September 2020


Simple Summary: The aim of this study was to gain a better understanding of cancer stem cells, which
are a small subpopulation of tumor cells with high plasticity driving tumor growth and metastasis.
Here we isolated two novel colorectal cancer cell lines originating from a rectal neuroendocrine
carcinoma and a colorectal adenocarcinoma, depicting stem-like properties. These in vitro models offer
the possibility to evaluate pathophysiological mechanisms in order to develop tailored therapeutic
strategies for distinct colorectal malignancies. Investigations revealed gene copy number gain of the
N-myc proto-oncogene for both. Accordingly, inhibition of the protein–protein interaction of myc and
N-myc proto-oncogenes with the myc-associated factor X utilizing small molecule KJ-Pyr-9, exhibited
a significant reduction in survival of both cell lines by the induction of apoptosis. Consequently, the
blockage of these interactions may serve as a possible treatment strategy for colorectal cancer cell
lines with gene copy number gain of the N-myc proto-oncogene.
Abstract: Cancer stem cells (CSC) are crucial mediators of cancer relapse. Here, we isolated
two primary human colorectal cancer cell lines derived from a rectal neuroendocrine carcinoma
(BKZ-2) and a colorectal adenocarcinoma (BKZ-3), both containing subpopulations with potential
stem-like properties. Protein expression of CSC-markers prominin-1 and CD44 antigen was
significantly higher for BKZ-2 and BKZ-3 in comparison to well-established colon carcinoma cell lines.
High sphere-formation capacity further confirmed the existence of a subpopulation with potential
stem-like phenotype. Epithelial–mesenchymal transition markers as well as immune checkpoint
ligands were expressed more pronounced in BKZ-2. Both cell populations demonstrated N-myc
proto-oncogene (NMYC) copy number gain. Myc proto-oncogene (MYC)/NMYC activity inhibitor
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all-trans retinoic acid (ATRA) significantly reduced the number of tumor spheres for both and the
volume of BKZ-2 spheres. In contrast, the sphere volume of ATRA-treated BKZ-3 was increased, and
only BKZ-2 cell proliferation was reduced in monolayer culture. Treatment with KJ-Pyr-9, a specific
inhibitor of MYC/NMYC-myc-associated factor X interaction, decreased survival by the induction
of apoptosis of both. In summary, here, we present the novel colorectal cancer cell lines BKZ-2 and
BKZ-3 as promising cellular in vitro models for colorectal carcinomas and identify the MYC/NMYC
molecular pathway involved in CSC-induced carcinogenesis with relevant therapeutic potential.
Keywords: colorectal cancer stem cells; NMYC; MYC; ATRA; EMT; KJ-Pyr-9; rectal neuroendocrine
carcinoma; colorectal adenocarcinoma
1. Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and second most common
cause of cancer-related mortality, with 1.8 million new cases and approximately 861,000 deaths in 2018
as reported by the World Health Organization (WHO) GLOBOCON database [1]. CRC comprises
the development of malignancies in the colon (72%) and the rectum (28%) and is the most common
malignancy in the gastrointestinal tract [2], with 90% of all CRCs being an adenocarcinoma (AC)
originating from epithelial mucosa cells [3]. A comparatively rare and poorly understood subtype of
CRC is the neuroendocrine carcinoma (NEC), representing a subgroup of neuroendocrine neoplasms
comprised of poorly-differentiated neoplasms originating from epithelial cells of the endocrine or
nervous system [4]. According to the WHO classification of 2010, colorectal gastro-entero-pancreatic
neuroendocrine-carcinoma (GEP-NEC) is a rare and aggressive variant of neuroendocrine tumors
(NET) as well as CRC with more than one third having metastatic disease at the time of diagnosis [5,6].
To evaluate pathophysiological mechanisms and therapeutic strategies for CRCs, preclinical
models were developed based on stable cell lines. However, latter are scarce especially for GEP-NECs
and were mainly established from metastatic spread [7–11]. Although some established cellular model
lines were derived from primary native tumor tissue [7,8,12], such cell lines still lack cancer stem cell
characteristics. Cancer stem cells (CSC) are a small subpopulation of tumor cells of high plasticity
driving tumor growth, repopulation after injury, and metastasis in a broad range of solid tumors
including CRC [13,14]. Next to mediating invasiveness and resistance to chemotherapy, CSC also use
immune system escape and are thus crucial mediators of cancer relapse. Next to in vitro propagation
as spheres [14–17], cancer stem cell markers like prominin-1 (CD133) and CD44 antigen (CD44) are
frequently used to identify cancer stem cells in CRC [3,6]. Important regulators of cancer stem cell
characteristics particularly include the members of the MYC transcription factor family, consisting of
L-, N-, and CMYC. In colorectal cancer stem cells (CCSC) the myc proto-oncogene protein (MYC) was
reported to be consistently overexpressed, contributing to self-renewal and pluripotency as well as
drug resistance [18–20]. Moreover, the overexpression of N-myc proto-oncogene protein (NMYC) was
detected for different tumor types, most notably for cancers of neural and neuroendocrine origin [21],
making the MYC-family a highly promising therapeutic target.
Next to the influence of the MYC-family to the tumor development, recent studies showed a direct
influence of MYC on the formation of metastasis by colon cancer cells in vivo [22]. Here, the authors
reported that the drug Astaxanthin increases the expression of micro ribonucleic acid (miRNA)-29a-3p
and miRNA-200a by the transcriptional repression of MYC. This repression leads to the abrogation of
their downstream target genes matrix metallopeptidase 2 and zinc finger E-box binding homeobox
1 (ZEB1), and consequently to the suppression of epithelial–mesenchymal transition (EMT) and
metastasis [22]. The process of EMT, during which epithelial cells acquire fibroblast-like properties and
show reduced intercellular adhesion and increased motility, allows the tumor cells to metastasize and
establish secondary tumors at distant sites [23,24]. Additionally, Xu and coworkers discovered that cells
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undergoing EMT acquire stem cell-like characteristics, thus providing a further link between EMT and
stem cell pathways, making EMT to a possible therapeutic target, too [25]. Differentiation therapy using
retinoic acids, especially all-trans retinoic acid (ATRA), showed clinical potential for different cancer
types, including breast cancer [26], neuroblastoma [27], glioblastoma [28], and CRC [29]. However,
ATRA is only clinically used for the treatment of acute promyelocytic leukemia [30]. In CRC cell lines
treatment with ATRA led to decreased proliferation, sphere formation and aldehyde dehydrogenase
(ALDH) + CSC-population size by inducing neuroendocrine differentiation [29]. Moreover, Shi and
colleagues found evidence that ATRA reverses EMT in chemotherapy resistant CRC cell lines [31].
Furthermore, a study with NMYC-amplified neuroblastoma cells could show that a combined treatment
of ATRA and a peptide derived from tenascin-C induced differentiation and led to a decrease of NMYC
protein [27], highlighting the involvement of ATRA in NMYC signaling.
In the present study, we established the first primary rectal GEP-NEC cell line named BKZ-2, as
well as a primary colonic AC cell line named BKZ-3 enriched for a subset of cells with markers of
stemness and EMT as a pre-clinical model system. Beyond the validation of these cell lines having a
subpopulation of cells with potential stem-like properties, we detected in each a genetic amplification
of the oncogene NMYC. Although MYC/NMYC inhibition using KJ-Pyr-9 led to a significant decrease
of survival of both cell lines, KJ-Pyr-9-treated BKZ-3 cells revealed a higher survival rate than BKZ-2.
Additionally, we show that ATRA-treatment of BKZ-2 cells decreased sphere volume as well as
total cell mass and seems to induce differentiation, as well as it decreased proliferation of BKZ-2
in monolayer. In contrast, ATRA-treatment of BKZ-3 led to an increase in sphere volume with no
alteration in total cell mass or proliferation in monolayer. Next to our findings that targeting NMYC
could have therapeutic activity in CRC patients, the establishment of those primary cell lines also
highlights the differences in CCSC. Moreover, the isolation of BKZ-2 and BKZ-3 offers the possibility to
evaluate further pathophysiological mechanisms systematically in order to develop tailored therapeutic
strategies for distinct colorectal malignancies.
2. Results
2.1. Tumor Characterization
An endoscopically retrieved bioptic sample of the primary tumor of patient 1 (Figure 1A–D)
revealed the pathological diagnosis of a rectal NET with G3 differentiation and 25% proliferation
marker protein Ki-67 (KI67) expression (Figure 2H). It was 100% positive for epithelial marker
pan-cytokeratin (panCK), 40% positive for special AT-rich sequence-binding protein 2 (SATB2), 10%
positive for neural cell adhesion molecule (CD56) and 100% positive for Synaptophysin (Figure 2A–D)
characterizing the colorectal tumor as large cell GEP-NEC according to the WHO-classification of
2010. It was tested negative for cytokeratin 20 (CK20), cytokeratin 7 (CK7) and homeobox protein
CDX-2 (CDX2) (Figure 2E–G). Next to the immunopathological analysis of the tissue, we performed an
immunohistochemical staining for the proto-oncogenes MYC and NMYC, which were both positive
(Figure 2I–L). Analysis of the expression of the immune checkpoint ligand programed death ligand 1
(PDL1) was done according to international standards by calculating combined positive score (CPS)
and tumor proportion score (TPS), as described in the material and methods section (Formulas (3)
and (4)). Quantification revealed 2% of PDL1 positive non-necrotic tumor cells. Analysis of the
percentage of PDL1 positive vital (non-necrotic) tumor cells, lymphocytes and macrophages were
done by calculating CPS and revealed a score of 2. Quantification of PDL1 positive lymphocytes,
macrophages, dendritic cells and granulocytes per tumor area displayed an immune cell score (IC) of 1
(Figure 2M, Formula (5)). There was no micro-satellite-instability nor positivity for human epidermal
growth factor receptor (EGFR) 2. Kirsten rat sarcoma 2 viral oncogene homolog/neuroblastoma rat
sarcoma viral oncogene homolog evaluation revealed a wild type.
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Figure 1. Clinical imaging derived from the two donors of the colorectal cancer cell lines. Patient BKZ-
2: (A) Computerized tomography (CT)-scan with demonstration of a rectal stenotic mass (orange 
arrows) with pre-stenotic obstructed bowel (yellow double arrow). Endoscopic appearance of 
carcinoma BKZ-2 (B) with intestinal discharge following (C) endoscopic bowel stenting of the 
neoplastic stenosis. (D) Staging CT-scan visualizing hepatic metastases (orange arrows). Patient BKZ-
3: (E) CT-scan indicating the neoplastic mass of the left colon (orange arrows) with pre-stenotic 
obstructed bowel (yellow double arrows). 
Figure 1. linical i aging derived fro the t o donors of the colorectal cancer cell lines. Patient BKZ-2:
(A) Computerized tomography (CT)-scan with demonstration of a rectal stenotic mass (orange arrows)
with pre-stenotic obstructed bowel (yello double arrow). Endoscopic appearance of carcinoma
BKZ-2 (B) with intestinal discharge following (C) endoscopic bowel stenting of the neoplastic stenosis.
(D) Staging CT-scan visualizing hepatic metastases (orange arrows). Patient BKZ-3: (E) CT-scan
indicating the neoplastic mass of the left colon (orange arrows) with pre-stenotic obstructed bowel
(yellow double arrows).
Histopathological examination of a bioptic sample retrieved from the primary tumor of patient 2
(Figure 1E) revealed the diagnosis of a colorectal AC. Carcinoma tissue was 100% positive for SATB2,
95% positive for CK20 and positive for KI67 with 50% being highly positive and 25% expressing
moderate levels of KI67 (Figure 2P–R). Analysis of the expression of PDL1 revealed 0% of PDL1
positive vital tumor cells. However, CPS was 3 for the adenocarcinoma tissue and IC was 1 (Figure 2S).
Further, it was tested negative for CK7 and Synaptophysin, characterizing the tumor as a colorectal AC
(Figure 2N,O). Analysis of the two oncogenes MYC and NMYC revealed positivity of the tissue for
both (Figure 2T–W).
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Figure 2. Immunohistochemical characterization of the primary rectal large cell neuroendocrine carcinoma
(NEC) and the colorectal adenocarcinoma (AC). NEC tissue was tested positive for (A) Synaptophysin,
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(B) neural cell adhesion molecule (CD56), (C) epithelial marker pan-cytokeratin (panCK) and (D) special
AT-rich sequence-binding protein 2 (SATB2), but was negative for (E) cytokeratin 20 (CK20) and
(F) cytokeratin 7 (CK7). Moreover, immunohistological staining for (G) the intestinal differentiation
marker homeobox protein CDX2 was negative. (H) Staining for the proliferation marker protein
Ki-67 (KI67) revealed 25% positive cells. Further immunohistochemical stainings of the NEC tissue
displayed positivity for the (I/J) myc proto-oncogene protein (MYC) and (K/L) N-myc proto-oncogene
protein (NMYC). (M) Immunohistochemical staining for programed death ligand 1 (PDL1) revealed
only slight expression with 2% of vital tumor cells being positive. AC tissue was tested negative
for neuroendocrine marker (N) Synaptophysin and (O) CK7, but was positive for (P) CK20 and
(Q) SATB2. AC revealed (R) 50% KI67 highly positive cells and 25% cells with moderate KI67
expression. (S) Immunohistochemical characterization of PDL1 expression displayed 0% positive vital
tumor cells, but revealed positivity for both (T/U) MYC and (V/W) NMYC in the AC tissue.
2.2. BKZ-2 and BKZ-3 Demonstrate Characteristics of Stemness and EMT–Relation to Immune Response
Involved Targets
We established colorectal cancer cell lines BKZ-2 and BKZ-3 derived from primarily resected
native tumor tissue (Figure 3A–C) by mechanical and enzymatic disintegration of the tissue sample.
Subsequent cultivation within Dulbecco’s Modified Eagle’s Medium/Ham’s -F12 supplemented with
epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), B27 and 10% fetal calf serum (FCS)
led to an adherently growing cell culture for both tumor tissue samples (Figure 3D,E). Initial culture
conditions were designed to obtain subpopulation of CSC from native tumor tissue. Analysis of
serine/threonine-protein kinase B-raf (BRAF) gene mutations displayed wild type alleles of BRAF for
exon 11 and 15 for both parental tumor tissue and isolated BKZ-2 and BKZ-3 cells. To confirm the
stem-like nature of BKZ-2 and BKZ-3, we tested the sphere formation capacity of both cell populations.
Both BKZ-2 and BKZ-3 formed spheres under serum-free conditions and supplementation with
heparin (Figure 3F,H). Quantification of the averaged sphere diameter of BKZ-2 and BKZ-3 revealed a
significant difference of the sphere-formation capacity for all three different heparin concentrations
and time points in comparison to the control. Moreover, the increase in sphere diameter of BKZ-2 was
significant with a peak value of 61.9 µm (±0.35) in the approach with 4 µg/mL heparin after 7 days
of culture. However, the increase in sphere diameter of BKZ-3 cells was not significant, although
there was also a tendency to form larger spheres over time with the highest value of sphere diameter
of 61.9 µm (±3.95) after the addition of 4 µg/mL heparin and cultivation for one week (Figure 3G,I).
Quantification of the population doubling time of BKZ-2 and BKZ-3 in comparison to the established
colon adenocarcinoma cell line HT-29 and colon carcinoma cell line HCT-116, revealed a significantly
higher (p ≤ 0.01) population doubling time for BKZ-2 with 40.12 h (±1.56) in comparison to BKZ-3
with 21.88 h (±1.19). Furthermore, HT-29 displayed a population doubling time of 21.87 h (±0.12)
and HCT-116 of 18.14 h (±0.051), which were significantly lower than the newly described cell line
BKZ-2. In addition, BKZ-3 and HT-29 both displayed a significantly higher population doubling
time in comparison to HCT-116 (Figure 4A, Formulas (1) and (2)). Comparison of sphere formation
capacity of BKZ-2, BKZ-3, HT-29 and HCT-116, revealed a significantly higher (p ≤ 0.001) volume
of spheres formed by HT-29 and HCT-116 when compared to BKZ-2 and BKZ-3. Moreover, HT-29
spheres displayed a significantly (p ≤ 0.001) higher volume in comparison to HCT-116 (Figure 4B–F,
Formula (6)). Further quantification concerning the number of spheres in relation to the count of seeded
cells, showed more than double amount of sphere formation rates for BKZ-2 and BKZ-3 (p ≤ 0.05) in
comparison to HT-29 and HCT-116 (Figure 4G).
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Figure 3. Successful isolation of the rectal large cell neuroendocrine carcinoma (NEC)-derived cancer
cell line BKZ-2 and the colorectal adenocarcinoma (AC)-derived cancer cell line BKZ-3. (A) For the
isolation of those cell lines that contain a subpopulation of cells with potential stem-like properties a
tissue sample of either the (B) rectal large cell NEC or the (C) colorectal AC was obtained, mechanically
and enzymatically disintegrated, and cultivated in CSC medium supplemented with fetal calf serum
(FCS), leading to (D/E) adherent growing cells. (F/H) Cultivation of the cells with the addition of heparin
and in the absence of FCS led to the formation of spheres, further validating stem-like properties of
BKZ-2 and BKZ-3. (G/I) Quantification of the averaged sphere diameter showed a significant increase
after the addition of heparin in comparison to the control for BKZ-2 and BKZ-3, regardless of the
tested heparin concentrations. Moreover, BKZ-2 showed a continuous growth of the spheres over a
time-period of one week. Non-parametric Kruskal-Wallis test (p ≤ 0.05), followed by Dunn’s Multiple
Comparison post-hoc test. n = 5, *** p ≤ 0.001, ** p ≤ 0.01. Mean ± standard error of the mean (SEM).
n.d. = not detectable.
In addition to the sphere formation capacity, BKZ-2 and BKZ-3 express the prominent CSC-markers
CD133, CD44 and Nestin on protein level (Figure 5A–D and Figure S3). Immunocytochemical analysis
of CD133, CD44 and Nestin expression of colon adenocarcinoma cell line HT-29 and colon carcinoma
cell line HCT-116 only revealed slight expression of these CSC-markers (Figure 5E–H). Quantification of
the percentage of CD133 high, medium and low cells showed significantly (p ≤ 0.01) higher percentages
of CD133 high cells for BKZ-3 cells in comparison to BKZ-2, HT-29 and HCT-116. Moreover, HT-29 and
HCT-116 revealed significantly (p ≤ 0.01) more CD133 low cells in comparison to BKZ-3. Even though
BKZ-2 cells showed significantly more CD133 low cells in comparison to BKZ-3, HT-29 revealed
significantly more CD133 low cells when compared to BKZ-2. Additionally, BKZ-2 revealed more
CD133 medium cells when compared to HT-29 (Figure 5I). Quantification of CD44 expressing cells
revealed no difference between BKZ-2 and BKZ-3 concerning the percentage of CD44 high cells.
However, both cell lines showed significantly (p ≤ 0.01) more CD44 high expressing cells in comparison
to HT-29 and HCT-116 (Figure 5J). Thus, both HT-29 and HCT-116 revealed a tendency for higher
percentages of CD133 and CD44 low expressing cells, as percentage of CD44 medium expressing
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cells was significantly higher in BKZ-2 and BKZ-3, too (Figure 5I,J). Further flow cytometric analysis
concerning the ALDH activity of BKZ-2 and BKZ-3 showed that 7.93% of BKZ-2 and 26.14% of
BKZ-3 cells are ALDH high expressing cells (Figure 6), further showing that those cell lines contain a
subpopulation of cells with potential stem-like characteristics.Cancers 2020, 12, x 8 of 35 
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** p ≤ 0.01, * p ≤ 0.05. Mean ± SEM (standard error of the mean).
Cancers 2020, 12, 2582 9 of 34
Cancers 2020, 12, x 10 of 35 
 
 
Figure 5. BKZ-2 and BKZ-3 express higher amounts of prominin-1 (CD133) and CD44 antigen (CD44) 
in comparison to HT-29 and HCT-116. Immunocytochemical analysis of BKZ-2 and BKZ-3 displayed 
high positivity for the cancer stem cell (CSC)-markers (A/C) CD133, CD44 and (B/D) Nestin, 
validating the isolation of two new cell lines that contain a subpopulation of cells with potential stem-
like properties. Immunocytochemical analysis of the common colon carcinoma cell lines HT-29 and 
HCT-116 only displayed slight expression of the CSC-markers (E/G) CD133, CD44 and (F/H) Nestin. 
Figure 5. BKZ-2 and BKZ-3 express higher amounts of promini 3) and CD 4 antigen (CD44) in
comparison to HT-29 and HCT-116. Immunocytochemical analysis of BKZ-2 and BKZ-3 displayed high
positivity for the cancer stem cell (CSC)-markers (A/C) CD133, CD44 and (B/D) Nestin, validating the
isolation of two new cell lines that contain a subpopulation of cells with potential stem-like properties.
Immunocytochemical analysis of the common colon carcinoma cell lines HT-29 and HCT-116 only
displayed slight expression of the CSC-markers (E/G) CD133, CD44 and (F/H) Nestin. Quantification
of the percentage of (I) CD133 high, medium and low cells revealed a significantly elevated amount
of CD133 high BKZ-3 cells in comparison to BKZ-2, HT-29 and HCT-116. Moreover, the percentage
of HT-29 and HCT-116 CD133 low cells was significantly higher when compared to BKZ-2 and BKZ-3.
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Quantification of (J) CD44 high, medium and low cells displayed for both populations a significantly higher
percentage of CD44 high cells in comparison to HT-29 and HCT-116. Non-parametric Kruskal-Wallis
equality-of-populations rank test (p ≤ 0.05) followed by Mann-Whitney test (p ≤ 0.05). n = 3, ** p ≤ 0.01,
* p ≤ 0.05, ns = not significant. Mean ± SEM (standard error of the mean).
Cancers 2020, 12, x 11 of 35 
 
Quantification of the percentage of (I) CD133 high, medium and low cells revealed a significantly 
elevated amount of CD133 high BKZ-3 cells in comparison to BKZ-2, HT-29 and HCT-116. Moreover, 
the percentage of HT-29 and HCT-116 CD133 low cells was significantly higher when compared to 
BKZ-2 and BKZ-3. Quantification of (J) CD44 high, medium and low cells displayed for both 
populations a significa tly higher perce tage of CD44 high cells in comparison to HT-29 and HCT-
116. Non-parametric Kruskal-Wallis equality-of-populations rank test (p ≤ 0.05) followed by Mann-
Whitney test (p ≤ 0.05). n = 3, ** p ≤ 0.01, * p ≤ 0.05, ns = not significant. Mean ± SEM (standard error of 
the mean). 
 
Figure 6. BKZ-2 and BKZ-3 both show aldehyde dehydrogenase (ALDH) activity. Flow-cytometric-
analysis of ALDH activity of (B) BKZ-2 and (D) BKZ-3 revealed 7.993% ALDH high cells for BKZ-2 
and 26.141% ALDH high cells for BKZ-3 in comparison to the appropriate (A/C) control with the 
specific ALDH inhibitor diethylaminobenzaldehyde (DEAB). 
Figure 6. BKZ-2 and BKZ-3 both show aldehyde dehydrogenase (ALDH) activity. Flow-cytometric-analysis
of ALDH activity of (B) BKZ-2 and (D) BKZ- revealed 7.993% ALDH high cells for BKZ-2 and 26.141%
ALDH high cells for BKZ-3 in comparison to the appropriate (A/C) control with the specific ALDH
inhibitor diethylaminobenzaldehyde (DEAB).
Further investigation concerning the transcriptional profile of BKZ-2 and BKZ-3 in comparison
to human dermal fibroblasts (HDF) via quantitative polymerase chain reaction (qPCR) exhibited
the expression of CSC-markers CD133, CD44, leucine rich repeat containing G protein-coupled
receptor 5 (LGR5) and epithelial cell adhesion molecule (EPCAM) as well as the expression of SRY-box
transcription factor 2 (SOX2) and octamer-binding transcription factor 4 (OCT4) in both BKZ-2 and
BKZ-3. A statistical comparison of the transcription levels of BKZ-2, BKZ-3, and HDF revealed
significant differences in the expression of CD133 (p ≤ 0.05), with BKZ-3 revealing higher levels in
comparison to BKZ-2 and HDF and CD44 (p ≤ 0.05), with BKZ-2 showing higher expression level in
comparison to BKZ-3 and HDF (Figure 7A,B). Even though, LGR5 was significantly higher expressed in
BKZ-2 when compared to BKZ-3 (p ≤ 0.05), both BKZ-2 and BKZ-3 show significantly lower (p ≤ 0.05)
level in comparison to HDF (Figure 7C). Comparison of the endothelial and CSC-marker EPCAM
revealed significantly higher (p ≤ 0.05) expression for BKZ-3 in comparison to HDF, but no difference
between BKZ-2 and BKZ-3 (Figure 7D). SOX2 was significantly higher (p≤ 0.05) expressed in BKZ-2 and
BKZ-3 in comparison to HDF, with significantly higher (p ≤ 0.05) expression for BKZ-3 when compared
to BKZ-2 (Figure 7E). The pluripotency marker OCT4 did not show any statistical difference between
the two cell lines, but was significantly higher expressed in HDF in comparison to BKZ-3 (Figure 7F).
As phenotypic stemness often coincides with a pronounced ability to proliferate, to migrate and to
invade in consequence of EMT, we tested for EMT-markers such as snail family transcriptional repressor
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2 (SLUG), snail family transcriptional repressor 1 (SNAIL) and twist family bHLH transcription factor 1
(TWIST). Although the three key transcription factors of EMT were detectable in both cell lines, the
expression levels of BKZ-2 were significantly higher than the expression of BKZ-3 for TWIST (p ≤ 0.05)
and especially for SLUG (p ≤ 0.05). Moreover, SNAIL was expressed significantly higher in BKZ-2
and BKZ-3 in comparison to HDF (Figure 7G–I). Further, we tested for immune response checkpoint
related ligands PDL1 and programmed death ligand 2 (PDL2). Transcriptional analysis revealed an
expression of both PDL1 and PDL2 in BKZ-2 and BKZ-3, with PDL2 being higher expressed than PDL1.
Quantification displayed a significantly higher expression of PDL1 (p ≤ 0.05) and PDL2 (p ≤ 0.05) for
BKZ-2 in comparison to BKZ-3 and HDF (Figure 7J,K).Cancers 2020, 12, x 12 of 35 
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nuclear staining for BKZ-2 (Figure 8A). Moreover, BKZ-3 was also tested positive for Synaptophysin 
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Figure 7. BKZ-2 and BKZ-3 show higher mess ibonucleic acid (mRNA)-level of canc r st m cell
(CSC)- and epithelial-mesenchymal-transition ( arkers as well as i mune heckpoint ligands
in comparison to human dermal fibroblasts (H F). uantitative polymerase chain reaction revealed
an expression of CSC-markers (A) prominin-1 (CD133), (B) CD44 antigen (CD44), (C) leucine rich
repeat containing G protein-coupled receptor 5 (LGR5), (D) epithelial cell adhesion molecule (EPCAM),
(E) SRY-box transcription factor 2 (SOX2) and (F) octamer-binding transcription factor 4 (OCT4) in
both cell lines. Comparison of the two cell lines, demonstrated significant differences of the relative
mRNA expression for CD133, CD44, LGR5 and SOX2. Further analysis revealed an expression of the key
transcription factors of the process of EMT (G) twist family bHLH transcription factor 1 (TWIST), (H) snail
family transcriptional repressor 2 (SLUG) and (I) snail family transcriptional repressor 1 (SNAIL), with
TWIST and SLUG being sig ificantly different expressed in BKZ-2 an BKZ-3. Moreover, quantification
display d a sign ficantly altered expression of the immune checkpoint ligands (J) programmed death
ligand 1 (PDL1) and (K) programmed death lig d 2 (PDL2) in the two cell lines. Non-parametric
Mann-Whitney-test (p ≤ 0.05). n = 3, * p ≤ 0.05. Mean ± SEM (standard error of the mean).
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2.3. BKZ-2 and BKZ-3 Feature Neuroendocrine, Neural Crest and Neuronal Characteristics
In a next step, we tested whether BKZ-2 share both neuroendocrine as well as neuronal
characteristics respectively as a cell line derived from a rectal carcinoma typed as a neuroendocrine
carcinoma. Synaptophysin was expressed on protein level confirmed by immunocytochemistry as
nuclear staining for BKZ-2 (Figure 8A). Moreover, BKZ-3 was also tested positive for Synaptophysin
(Figure 8C). Quantification of the percentage of nuclear Synaptophysin positive cells revealed 90.27%
(±2.73) for BKZ-2 and 92.92% (±6.45) for BKZ-3 (Figure 8E). Further quantification concerning
Synaptophysin high and low nuclei displayed significantly more high nuclei (p ≤ 0.05) for BKZ-2 in
comparison to BKZ-3. However, both cell populations revealed significantly more Synaptophysin low
(p ≤ 0.01) nuclei in comparison to Synaptophysin high (Figure 8G).
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92.57% positive cells for BKZ-3. (H) Comparison of SLUG high and low cells displayed a significantly 
higher amount of SLUG high cells of BKZ-2 when compared to BKZ-3. Moreover, BKZ-3 cells in 
general showed a significantly higher percentage of SLUG low cells in comparison to the amount of 
Figure 8. BKZ-2 cells reveal higher levels of Synaptophysin (SYP) and snail family transcriptional
repressor 2 (SLUG) protein in comparison to BKZ-3 cells. Immunocytoc emical stainings revealed the
expression of neuroendocrine and cancer stem cell marker (A/C) Synaptophysin as well as the expression
of (B/D) SLUG, one of the key transcription factors of the process of epithelial to mesenchymal transition
in both populations. (E) Quantification of cells po tive for nucle r Synaptophysin revealed a mean of
90.27% for BKZ-2 and 92.92% for BKZ-3. (G) Further classification in Synaptophysin high and low cells,
showed a significantly higher amount of Synaptophysin low nuclei in comparison to Synaptophysin
high nuclei for both BKZ-2 and Z-3. H wever, BKZ-2 revealed a significantly higher percentage of
Synaptophysin high nuclei in comparison to BKZ-3. (F) Quantification of nuclear positivity for SLUG
displayed 100% positive cells for BKZ-2 and a mean of 92.57% positive cells for BKZ-3. (H) Comparison
of SLUG high and low cells displayed a significantly higher amount of SLUG high cells of BKZ-2 when
compared to BKZ-3. Moreover, BKZ-3 cells in general showed a significantly higher percentage of
SLUG low cells in comparison to the amount of SLUG high cells. Non-parametric Mann-Whitney-test
(p ≤ 0.05). n = 3, ** p ≤ 0.01, * p ≤ 0.05, ns = not significant. Mean ± SEM (standard error of the mean).
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As neural crest characteristics are strongly related to the EMT process, we also investigated the
expression of key transcription factor SLUG and neural crest and calcium binding protein S100 (S100)
on protein level. Immunological staining displayed a strong expression of nuclear SLUG in both
BKZ-2 and BKZ-3, representing an EMT-phenotype (Figure 8B,D). Quantification of the amount of
nuclear SLUG positive cells displayed 100% positive BKZ-2 cells and 92.57 (±3.71) positive BKZ-3 cells
(Figure 8F). Further quantification revealed significantly more (p ≤ 0.01) SLUG high cells for BKZ-2
in comparison to BKZ-3. Additionally, BKZ-3 cells showed significantly more (p ≤ 0.01) SLUG low
cells when compared to the amount of SLUG low BKZ-2 cells and SLUG high BKZ-3 cells (Figure 8H).
Moreover, S100 could be detected nuclear as well as cytoplasmatic in both cell lines (Figure S1A,E). Next,
further traits of neuronal differentiation utilizing a comprehensive panel of neuronal markers were
evaluated. Examined by immunocytochemistry, BKZ-2 and BKZ-3 were positive for cytosolic vesicular
glutamate transporter 2 (vGLUT2), cytosolic dopamine and mainly nuclear tyrosine hydroxylase
(TH), highlighting their neuronal characteristic. Moreover, the nuclear expression of TH indicates an
undifferentiated phenotype, further suggesting stemness-like features of a subpopulation of BKZ-2
and BKZ-3 since TH was also detectable in the nuclei of BKZ-3 (Figure S1B–D,F–H). HDF were used as
negative control for all immunocytochemical stainings (Figure S2A–J).
2.4. ATRA-Treatment Leads to a Contrary Switch in Growth Habits of BKZ-2 and BKZ-3
Next we investigated the influence of ATRA on BKZ-2 and BKZ-3 cells as ATRA was shown to decrease
proliferation, sphere formation and CSC population size in CRC cell lines. For this, sphere-formation
capacity of BKZ-2 and BKZ-3 was analyzed after treatment with different ATRA concentrations. After five
days of culture, volume, and number of spheres of BKZ-2 were quantified, revealing a significant decrease
of sphere volume (p ≤ 0.001) after cultivation with 1, 5, or 10 µM ATRA (Figure 9E, Formula (6)).
Furthermore, there was a non-significant trend of reduced number of spheres formed by BKZ-2 when
co-incubated with ATRA regardless of used concentration (Figure 9F). Representative images of each
treatment condition suggested the induction of a differentiation towards fibroblast-like morphology of
BKZ-2 upon ATRA-treatment with cells becoming more adherent (Figure 9A–D).
A corresponding experiment was performed for BKZ-3, however unexpectedly results were
opposed to those for BKZ-2. Quantification revealed no significant decrease as for BKZ-2, but a
significant increase in sphere volume of BKZ-3 after 10 µM ATRA-treatment (p ≤ 0.001) (Figure 9G–K).
In contrast to the increase of sphere volume, number of spheres formed by BKZ-3 declined significantly
when treated with 10 µM ATRA (p ≤ 0.05) (Figure 9L), suggesting a switch in the growth behavior
of BKZ-3 upon ATRA stimulation. A direct comparison of the volume of formed spheres by BKZ-2
and BKZ-3 revealed a statistically significant difference between the volumes of spheres induced by
ATRA stimulation (p ≤ 0.05). The sphere volume of BKZ-3 was significantly higher in comparison
to BKZ-2 independent of ATRA concentration (Figure 10A). Additionally, calculation of the total cell
mass of BKZ-2 and BKZ-3 by multiplying the mean of the volume with the mean of sphere number
exhibited a significant decrease for BKZ-2 (p ≤ 0.05), but no alteration in cell mass for BKZ-3 upon
ATRA-treatment (Figure 10B). Thus, ATRA stimulation seems to lead to a switch in growth behavior
of spheres in both cell lines, however BKZ-2 cells seem to switch to a more differentiated phenotype
with less total cell mass and BKZ-3 cells generate bigger but fewer spheres without any significant
change in total cell mass. Next to the analysis of the influence of ATRA on sphere formation of BKZ-2
and BKZ-3, its influence on monolayer cultures was investigated. For this, BKZ-2 and BKZ-3 cells as
monolayers were treated for five days with different ATRA concentrations. Afterwards, the cell count
was determined utilizing OranguTM (Cell Guidance Systems, Cambridge, UK). Statistical analysis
revealed a significant decrease (p ≤ 0.05) in cell count for BKZ-2 cells after ATRA-treatment, but not for
BKZ-3 (Supplementary Figure S4A,B). Further immunocytochemical stainings for cleaved caspase 3
protein after ATRA-treatment of BKZ-2 and BKZ-3 did not showed any positivity for this apoptosis
marker, suggesting an influence of ATRA on cell proliferation only (Figure S4C–J). Finally, BKZ-2 and
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BKZ-3 seem to behave differently in relation to ATRA, even though ATRA reduced the number of
formed spheres for both cell populations.
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Figure 9. All-trans retinoic acid (ATRA) reduce number of BKZ-2 and BKZ-3 formed spheres respectively,
but cause opposed effects concerning sphere volume of BKZ-2 and BKZ-3. Cells were cultured in an amount
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of 5000 cells per 200 µL cancer stem cell (CSC) medium containing 4 µg/mL heparin in a low adhesion
96 well-plate. Medium was supplemented with (A/G) dimethylsulfoxide, (B/H) 1 µM ATRA, (C/I) 5 µM
ATRA or (D/J) 10 µM ATRA. (A–D) Representative images already display a morphological change
of BKZ-2 after the cultivation with 1 µM ATRA, indicated by the adherence of the cells (arrows).
Quantification of the (E) volume of spheres formed by BKZ-2 cells showed a significant decrease after
ATRA-treatment. Further quantification concerning (F) the number of spheres revealed a tendency
for fewer spheres after ATRA-treatment for BKZ-2. (G–J) Representative images of BKZ-3 spheres
and quantification of the (K) volume of spheres formed by BKZ-3 cells showed a significant increase
subsequent to treatment with 10 µM ATRA. Further quantification concerning the (L) number of
spheres revealed a significant decrease of the number of spheres after the treatment with 10 µM ATRA.
Non-parametric Mann-Whitney-test (p ≤ 0.05). n = 3, *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05. Mean ± SEM
(standard error of the mean).Cancers 2020, 12, x 17 of 35 
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MYC and NMYC were reported to play an important role for plasticity, proliferation and 
apoptosis in various entities of malignancies. To investigate a possible correlation of ATRA resistance 
and MYC/NMYC, we analyzed BKZ-2 and BKZ-3 regarding MYC/NMYC expression levels. First, we 
determined protein expression levels in BKZ-2 and BKZ-3 cells using immunocytochemistry, 
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NMYC was mainly detected cytosolic contrary to MYC, which was detected in the nuclei of BKZ-2 
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Figure 10. All-trans retinoic acid (ATRA)-treatment reduced total cell mass of BKZ-2 formed spheres,
but does not have an effect on total cell mass of BKZ-3 formed spheres. Analysis of the quantification
of the (A) volume of the spheres formed by the two colorectal cancer cell lines revealed a significant
difference after ATRA-treatment. ATRA-treatment led to the formation of significant bigger spheres
formed by BKZ-3 in comparison to BKZ-2. Further quantification of (B) the total cell mass revealed a
significantly decreased cell mass for BKZ-2 upon ATRA stimulation, while the total cell mass of BKZ-3
was not altered. No -parametric Mann-Whitney-test (p ≤ 0.05). n = 3, * p ≤ 0.05, ns = not significant.
Mean ± SEM (standard error of the mean).
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2.5. NMYC Copy Number Gain Sensitize BKZ-2 and BKZ-3 for MYC/NMYC Inhibitor Induced Apoptosis
MYC and NMYC were reported to play an important role for plasticity, proliferation and apoptosis
in various entities of malignancies. To investigate a possible correlation of ATRA resistance and
MYC/NMYC, we analyzed BKZ-2 and BKZ-3 regarding MYC/NMYC expression levels. First, we
determined protein expression levels in BKZ-2 and BKZ-3 cells using immunocytochemistry, revealing
the expression of NMYC and MYC in both. Although both oncogenes were expressed, NMYC was
mainly detected cytosolic contrary to MYC, which was detected in the nuclei of BKZ-2 and BKZ-3
(Figure 11A–D).
Further, relative haploid normalized gain in gene copy numbers of NMYC and MYC was
investigated for BKZ-2 and BKZ-3. Calculation of relative haploid copy number of NMYC displayed a
1.82 (±0.094)-fold amplification for BKZ-2 and a 1.45 (±0.24)-fold amplification for BKZ-3, indicating
a duplication of the NMYC gene in both cell lines (Figure 11E). No amplification was detected for
relative haploid gene copy number of MYC, as BKZ-2 represents a relative haploid copy number of
0.74 (±0.089) and BKZ-3 0.63 (±0.11) (Figure 11F). Thus, no differences in MYC and NMYC expression
could be detected for BKZ-2 and BKZ-3, suggesting additional molecular pathways involved in ATRA
mediated differentiation.
Previously, KJ-Pyr-9 as inhibitor of both MYC and NMYC showed proliferation inhibiting effects
on various tumor cell lines. Accordingly, we investigated this small molecule concerning its effect
on survival of BKZ-2 and BKZ-3 cells. After 120 h co-incubation with the inhibitor, survival rate of
both cell lines revealed a significant decrease (p ≤ 0.05) with increasing concentrations of KJ-Pyr-9
over 20 µM respectively. Moreover, discrepancies in the survival rates between both cell lines were
detected, represented by significantly higher (p ≤ 0.05) survival rates for BKZ-3 in comparison to
BKZ-2 after treatment with KJ-Pyr-9 independent on inhibitor concentrations (Figure 11G). Normalized
survival rate after stimulation with 10 µM KJ-Pyr-9 was 78.59% (±8.53) for BKZ-2 and 123.9% (±9.62)
for BKZ-3 and with 20 µM KJ-Pyr-9 4.12% (±1.09) for BKZ-2 and 16.89% (±6.61) for BKZ-3. Cultivation
with 40 µM KJ-Pyr-9 led to a survival rate of 6.19% (±1.14) for BKZ-2 and 19.85% (±1.42) for BKZ-3
and with 60 µM KJ-Pyr-9 to a survival of 11.18% (±0.92) for BKZ-2 and 27.11% (±0.97) for BKZ-3.
This significantly higher survival rate of BKZ-3 in contrast to BKZ-2 possibly demonstrates a higher
MYC/NMYC inhibitor tolerance of BKZ-3, suggesting a more MYC-independent growth behavior in
comparison to BKZ-2. This result stands in line with the here presented inefficient differentiation of
BKZ-3 using ATRA, which is also known to target MYC/NMYC activity. Comparison of survival rate of
BKZ-2 and BKZ-3 with the two colon carcinoma cell lines HT-29 and HCT-116 after KJ-Pyr-9-treatment
revealed a significantly higher (p ≤ 0.05) survival of BKZ-2 and BKZ-3 subsequent to treatment with
40 µM and 60 µM (Figure 11H). Survival rates following the addition of 40 µM KJ-Pyr-9 were 6.19%
(±1.14) for BKZ-2, 19.85% (±1.42) for BKZ-3, 2.83 (±0.12) for HT-29 and 1.78 (±0.27) and after 60 µM
11.18% (±0.92) for BKZ-2, 27.11% (±0.97) for BKZ-3, 3.18 (±0.16) for HT-29, and 1.93 (±0.14) for HCT-116.
To address whether the reduction in survival is caused by regulation of proliferation or apoptosis BKZ-2
and BKZ-3 cells were treated with KJ-Pyr-9 as described before, followed by immunocytochemical
staining for cleaved caspase 3 to determine the number of apoptotic cells (Figure 12A–J). Quantification
of cleaved caspase 3 staining displayed a significantly higher (p ≤ 0.001) amount of apoptotic BKZ-2
cells with 93.65 (±6.35) after 10 µM KJ-Pyr-9 in comparison to BKZ-3 with 4.32 (±2.78). In accordance
with that, BKZ-3 displayed a trend for less cleaved caspase 3 positive cells after 20 µM of KJ-Pyr-9 with
91.89 (±4.62) in comparison to BKZ-2 with 100% apoptotic cells. However, BKZ-2 seem to be more
sensitive for KJ-Pyr-9 induced apoptosis, BKZ-2 and BKZ-3 showed 100% cleaved caspase 3 positivity
for KJ-Pyr-9-incubation with concentrations greater than 40 µM (Figure 12K).
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Figure 11. Inhibition of the myc proto-oncogene protein (MYC) and N-myc proto-oncogene protein
(NMYC) significantly decreases the survival rate of BKZ-2 and BKZ-3 cells. Immunocytochemical staining
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revealed a strong expression of the oncogene (A/B) NMYC, as well as a nuclear expression of the
oncogene (C/D) MYC, in both BKZ-2 and BKZ-3 on protein level. Evaluation of the haploid copy
number of the two oncogenes, demonstrated a two-fold increase of the haploid copy number of
(E) NMYC, but a normal haploid copy number for (F) MYC within both cell lines. To investigate the
influence of the MYC/NMYC inhibitor KJ-Pyr-9 on the proliferation, 3000 cells per 100 µL cancer stem
cell medium were cultured in a 96 well for 120 h with the inhibitor or dimethylsulfoxide and 10%
fetal calf serum. Afterwards, metabolism was measured using OranguTM (Cell Guidance Systems,
Cambridge, UK) and cell count was determined by using a standard curve. (G) Normalized survival
rate was quantified and significantly decreased after exposure to values greater than 20 µM of KJ-Pyr-9
in comparison to the control for BKZ-2 and BKZ-3. Further comparisons between the two cell
lines displayed a significant decrease of the survival rate of BKZ-2 in comparison to BKZ-3 for all
inhibitor concentrations. (H) Although comparison of survival rates after KJ-Pyr-9-treatment showed
significantly higher survival of HCT-116 when compared to BKZ-2 after 20 µM K-Pyr-9, cell survival of
BKZ-2 and BKZ-3 was significantly improved in comparison to HT-29 and HCT-116 after treatment with
inhibitor concentrations over 40 µM. Non-parametric Mann-Whitney-test (p ≤ 0.05). n = 3, * p ≤ 0.05.
Mean ± SEM (standard error of the mean).
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Figure 12. Myc proto-oncogene (MYC)/N-myc proto-oncogene (NMYC) inhibitor KJ-Pyr-9 induces 
apoptosis of BKZ-2 and BKZ-3. Representative images of immunocytochemical staining for cleaved 
caspase 3 (CASP3) after KJ-Pyr-9-treatment of (A–E) BKZ-2 and (F–J) BKZ-3. (K) Quantification of the 
percentage of cleaved CASP3 positive cells after the addition of 10 μM KJ-Pyr-9 revealed a 
significantly higher amount for BKZ-2 with about 94% in comparison to BKZ-3 with about 4%. 
However, concentrations higher than 40 μM lead to 100% cleaved CASP3 positive cells for BKZ-2 and 
BKZ-3. Student’s t-test (p ≤ 0.05). n = 3, *** p ≤ 0.001. Mean ± SEM (standard error of the mean). 
3. Discussion
In this study, we present the establishment of two primary human colorectal cancer cell lines 
that contain a subpopulation with potential stem-like properties. One very rare case of a GEP-NEC 
of the rectum is named BKZ-2 and one colorectal AC is referred to as BKZ-3. We characterized 
stemness-like properties by high CD133 and CD44 expression, relatively slow proliferation rates, and 
high number of formed spheres in the in vitro model systems, providing the basis for further 
exploration of patho-mechanisms in order to develop therapeutical strategies. As initial steps to that 
respect, we further tested for the impact and role of ATRA and the MYC/NMYC inhibitor KJ-Pyr-9 
in these cells, as both are interfering with MYC/NMYC signaling in CCSC. However, some limitations 
Figure 12. Myc proto-oncogen (MYC)/N-myc t - cogene (NMYC) inhibitor KJ-Pyr-9 induces
apoptosis of BKZ-2 and BKZ-3. Representative i ages of i munocytochemical staining for cleaved
caspase 3 (CASP3) after KJ-Pyr-9-treatment of (A–E) BKZ-2 and (F–J) BKZ-3. (K) Quantification
of the percentage of cleaved CASP3 positive cells after the addition of 10 µM KJ-Pyr-9 revealed a
significantly higher amount for BKZ-2 with about 94% in comparison to BKZ-3 with about 4%. However,
concentrations higher than 40 µM lead to 100% cleaved CASP3 positive cells for BKZ-2 and BKZ-3.
Student’s t-test (p ≤ 0.05). n = 3, *** p ≤ 0.001. Mean ± SEM (standard error of the mean).
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3. Discussion
In this study, we present the establishment of two primary human colorectal cancer cell lines
that contain a subpopulation with potential stem-like properties. One very rare case of a GEP-NEC
of the rectum is named BKZ-2 and one colorectal AC is referred to as BKZ-3. We characterized
stemness-like properties by high CD133 and CD44 expression, relatively slow proliferation rates,
and high number of formed spheres in the in vitro model systems, providing the basis for further
exploration of patho-mechanisms in order to develop therapeutical strategies. As initial steps to that
respect, we further tested for the impact and role of ATRA and the MYC/NMYC inhibitor KJ-Pyr-9 in
these cells, as both are interfering with MYC/NMYC signaling in CCSC. However, some limitations of
this study should be noted, as identification of the subpopulation with stem cell-like properties was
only done by in vitro not in vivo experiments.
CCSC are defined with a group of cell surface markers such as CD44, CD133, EPCAM and
LGR5 [32,33], which all were tested positive in BKZ-2 and BKZ-3 cells on transcriptional and/or
on protein level. CD133 is a robust biomarker to identify primary CSC and can be proposed as a
prognostic marker of CRC patients. Moreover, it is reported to be expressed in poorly-differentiated
NECs and well-differentiated NETs of the digestive tract [34] and was demonstrated to be expressed
in CCSC-lines [35]. It is the most well-known marker for the isolation and investigation of CSC in
different types of cancer [36–38] and known to be responsible for radio- and chemotherapy-resistance
in CCSC [39,40]. However, it seems to be more reliable to use CD133 in combination with other
markers, such as CD44 as target biomarkers for the isolation of CCSC in both cell lines and primary
tumor cell populations as done in our study [6]. CSC-marker CD44 is known to mediate cancer cell
survival, proliferation, and motility, as well as the modulation of tumor microenvironment [36,41,42],
indicating CD133 and CD44 as an excellent marker set to validate a CCSC-like-phenotype. Next to the
protein expression of CD133 and CD44, class VI intermediate filament protein Nestin was shown to be
expressed in both cell lines, further confirming potential stem-like properties of BKZ-2 and BKZ-3 as
Nestin is commonly accepted to play a role in CSC-phenotypes, particularly regarding the capacity for
self-renewal [43]. Additionally, in vitro tumorigenicity, as proven here for BKZ-2 and BKZ-3 utilizing
sphere formation assays and the higher number of formed spheres of BKZ-2 and BKZ-3 in comparison
to established colon carcinoma cell lines HT-29 and HCT-116, underline the existence of a subpopulation
with potential stem-like characteristics [15]. Moreover, sphere formation seems to be biologically
reliable as these in vitro testing modalities demonstrated uniformly results corresponding with murine
in vivo xenograft models if tested with the same cancer cells including NEC-cell lines [9,44,45]. Further
analysis of the proliferation and comparison of population doubling times of BKZ-2 and BKZ-3
with established colon carcinoma cell lines HT-29 and HCT-116, respectively, showed significantly
higher population doubling times for BKZ-2 and BKZ-3. This may be due to the fact, that CSC have
the ability to become more quiescent with slow proliferation rates to escape from chemotherapy.
These slow-cycling cells are tumorigenic and more resistant to traditional chemotherapies than rapidly
dividing cells [46,47]. Analysis of BRAF mutation status showed no mutation for codons 600, 464, 466,
and 469 in both parental tumor tissue and cell populations. Concerning BRAF mutation in CRC a
retrospective study showed that patients whose tumors had microsatellite stability with mutant BRAF
demonstrated significantly reduced overall survival [48]. However, only 6–18% of CRC patients harbor
a BRAF mutation [48–50].
Quantitative PCR analysis displayed LGR5 expression in both BKZ-2 and BKZ-3 cells. Nevertheless,
their expression levels were significantly lower in comparison to HDF. LGR5 is well-established as a
marker of native intestinal stem cells [51] as well as CCSC [52] and plays an active role in pathogenesis
of CRC [53]. Certainly, Fumagalli and colleagues observed most disseminated CRC cells in circulation
to be LGR5 negative. Latter cells formed distant metastases in which CSC appeared LGR5 positive [54].
This plasticity of CCSC may explain the relatively low level of LGR5, as BKZ-2 and BKZ-3 also revealed
an EMT-phenotype reflected by a high level of SLUG. Positivity in BKZ-2 and BKZ-3 cells for the 40 kDa
single transmembrane protein EPCAM encoded by tumor-associated calcium signal transducer-1
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gene [55] was relevant as epithelial adhesion molecule playing a role in carcinogenesis of epithelial cells
by activating expression of proto-oncogenes MYC and CYCLIN A/E [56]. Further, it was demonstrated
to correlate with the level of malignancy in foregut-NET of the pancreas [57]. It was also shown
to be involved in regulation of intercellular adhesion-mediated signal transduction, cell migration,
proliferation and differentiation [55]. Significantly higher expression of SOX2 was observed in primary
CRC tissues and metastatic tumor tissues compared to paratumoral tissues with 80% of the analyzed
primary tumor samples [58]. Further, in a CRC-derived CSC-line (SW620) [59], SOX2 was associated
with cell migration, invasion, colony formation and tumorigenesis as well as with spherogenicity
and chemoresistance [58], representing SOX2 as a CSC-marker. Interestingly, a knock-down of SOX2
in SW620 cells induced a mesenchymal–epithelial transition process, reducing the migration and
invasion capabilities of cells [60], and suggesting a link between EMT and stemness. SOX2 as well
as CSC-marker OCT4 were expressed in BKZ-2 and BKZ-3. However, OCT4 expression was also
prominent in HDF, which is not unexpected as fibroblasts are able to express OCT4 under different
cell culture microenvironmental conditions [61]. Expression of CD133, CD44, EPCAM, SOX2, and
OCT4 substantiates that BKZ-2 and BKZ-3 include a subpopulation with potential stem-like properties.
Moreover, differences in messenger RNA (mRNA) expression levels of CD133, CD44, LGR5, and SOX2
between BKZ-2 and BKZ-3 possibly demonstrate a balance between different CSC-markers necessary
for CSC maintenance.
Histopathological analysis of Synaptophysin as a neuroendocrine marker within the tumor tissue
revealed expression only within NEC. However, immunocytochemically both, BKZ-2 and BKZ-3 were
demonstrated to be positive for Synaptophysin. This finding emphasizes that Synaptophysin not
only plays a role as neuroendocrine marker [62], but also as marker for stemness, as recently reported
by us [63]. Quantification of Synaptophysin in nuclei revealed significantly more highly positive
nuclei for BKZ-2 in comparison to BKZ-3, possibly reflecting the neuroendocrine origin or a potential
more stem cell-like phenotype. Further investigation on neuronal and neural-crest related protein
expressions displayed a strong expression of S100A1 for BKZ-2 and BKZ-3, which was shown to be
negatively associated with the frequency of lymph node metastasis and level of dedifferentiation in
ovarian cancer, enhancing the ovarian cancer cell proliferation and migration [64]. Further, S100A9
was shown to be required for the proliferation of CRC spheroids upon mammalian target of rapamycin
complex 1 signaling [65], suggesting a role of S100 family in stemness of CRC cells. Moreover, the
neuronal marker vGLUT2 [66], as well as the dopaminergic marker dopamine were detected in BKZ-2
and BKZ-3, highlighting the neuroendocrine origin of BKZ-2 and suggesting a neuronal differentiation
potential for BKZ-3, too [67]. TH protein, which is a rate-limiting enzyme of dopamine synthesis [68],
and thus a marker for dopaminergic neurons, was expressed predominantly nuclear, but also cytosolic
in BKZ-2 cells. Moreover, it could be detected in the nuclei of BKZ-3 cells, possibly reflecting the
multipotent phenotype of a subpopulation with potential stem cell-like characteristics, since mature
neurons would express TH predominantly cytosolic.
There is increasing evidence that CSC lay the foundation for cancer invasiveness. A critical role of
EMT and stemness for tumor plasticity and aggressiveness was discussed for NET variants of prostate
cancer in more depth [69–71] and to some extent for pancreatic neoplasms [72]. Additionally, targeting
cancer cells using ATRA-dependent differentiation therapy has been recently described for several
solid cancer types including CRC [29] and has been clinically proven for acute promyelocytic leukemia.
There are indications that ATRA suppresses proliferation, migration, CSC population size and sphere
formation of cancer cell lines by reversing EMT. During EMT, the E-cadherin promoter is frequently
repressed by specific transcriptional repressors, including SNAIL, SLUG, ZEB1, high mobility group
AT-hook 2, and TWIST, making E-cadherin expression a valuable prognostic factor of CRC [73]. We even
demonstrated for precursor lesions of CRC SNAIL-up- and e-cadherin-down-regulation, which was
not found in normal colorectal tissue [74]. In this study, BKZ-2 expressed higher level of the EMT key
transcription factors TWIST, SLUG, and SNAIL as well as SLUG on protein level in comparison to BKZ-3.
Thus, BKZ-2 seem to harbor a more pronounced EMT-phenotype in comparison to BKZ-3. Cui and
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coworkers demonstrated that ATRA induced differentiation by decreasing invasion, proliferation
and migration of the murine hepatocellular carcinoma cell lines hepa1-6. Moreover, they showed
impaired in vitro liver function upon the reversal of EMT [75]. Those results stand in line with the study
of Modarai and colleagues, in which ATRA-treatment of human CRC lines decreased proliferation,
sphere formation and ALDH + CSC population size by inducing neuroendocrine differentiation [29].
Within the presented study, this phenomenon was also shown for the neuroendocrine-derived cell
line BKZ-2, revealing a decreased sphere volume and reduction in total cell mass, which is probably
caused by decreased proliferation. Further, BKZ-2 cells seem to demonstrate a more differentiated
phenotype after ATRA-treatment. However, analysis of the ATRA effect on apoptosis revealed no
increase in apoptotic cells after ATRA-stimulation for BKZ-2 and BKZ-3. This suggests that ATRA
suppresses proliferation in neuroendocrine-derived colorectal cancer cells with potential stem-like
properties possibly by targeting an EMT-phenotype and inducing differentiation, as already shown for
human CSC of head and neck squamous carcinoma [76], glioblastoma multiforme [77], and gastric
cancer [78]. The AC-derived colorectal cancer cell line BKZ-3 exhibited lower mRNA levels of EMT
transcription factors as well as SLUG high nuclei and behaved contrary subsequent to ATRA-treatment,
as volume of spheres increased with no change in total cell mass. This possibly represents some
sort of ATRA resistance for BKZ-3 cells, even if ATRA induced a shift in growth behavior for BKZ-3
cells. There is growing evidence that mechanisms inducing the degradation of retinoic acid receptor
β [79] or cytoplasmic retinoid X receptor α play crucial roles in the ATRA resistance of colonic AC
cell lines [80]. A similar downregulation of retinoic acid receptors could explain the opposed effect
in BKZ-3 cells compared to BKZ-2, however the actual molecular pathway behind this still needs to
be clarified. The CSC-marker ALDH [81] is a key enzyme in retinoid acid signaling and was shown
to be targeted by ATRA in CRC cell lines [29]. Analysis of ALDH activity demonstrated a slightly
higher proportion of BKZ-3 cells with high ALDH activity of about 26% in comparison to BKZ-2 with
about 8% of highly active cells. However, Khorrami and coworkers have shown that HT-29-derived
colonospheres with low ALDH activity demonstrate increased tumorigenic potential and stemness
properties, reflecting the need for a set of CSC-marker and CSC plasticity. Even though it was presented
that ATRA treatment decreased colony and sphere formation capacities only in an ALDH-high not in
ALDH-low subpopulation of a human ovarian cancer cell line [82], the mechanism behind the higher
sensitivity of BKZ-2 in comparison to BKZ-3 cannot be explained solely by ALDH activity.
There is evidence that differentiation therapy using ATRA involves MYC/NMYC regulation in
cancer cells. This was shown by Farrell and coworkers, who validated that peptidyl-prolyl cis-trans
isomerase Pin1 (PIN1) regulates MYC activity by acting on MYC degradation and activation [83]. ATRA
acts as inhibitor of PIN1, reducing for example in vivo growth of triple-negative breast cancer xenografts
by the degradation of PIN1 protein [84]. This stands in line with results concerning hepatocellular
carcinoma xenografts using slow-release poly L-lactic acid microparticle containing ATRA [85].
Less sensitivity of BKZ-3 for ATRA-treatment was not reflected by differences in MYC-family member
protein expressions but may be due to dysregulation in PIN1 signaling, leading to less inhibitory
effects of ATRA on MYC activity. MYC-family proteins function as potent transcription factors that
organize multiple cellular processes, including adhesion, proliferation, survival, and differentiation.
Thus, MYC expression is frequently enhanced in cancer leading to elevated MYC RNA and protein
expression [86,87]. Likewise, we demonstrated gene copy number gain for NMYC in both colorectal
cancer cell lines that comprise a subpopulation of cells with potential stem-like properties. Gain of gene
copy numbers of members of the MYC-family is reported to be an independent factor for poor prognosis
in consecutive CRC patients and in the stage II–III subgroups [88]. Accordingly, neuroendocrine prostate
cancer tumors, associated with aggressive disease and poor prognosis, are partly driven by aberrant
expression of NMYC. NMYC overexpression and its subsequent deoxyribonucleic acid (DNA) binding
induce epigenomic and transcriptomic reprogramming, resulting in a castration-resistant, promoting
lineage-plasticity [21]. Further, NMYC overexpression was associated with highly proliferative,
invasive prostate cancer with neuroendocrine features and was associated with an induction of EMT
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genes and poor outcome [89]. In accordance to that, NMYC copy number gain of BKZ-2 and BKZ-3
correlated with the expression of EMT genes and stem-like characteristics. Moreover, NMYC copy
number gain of BKZ-2 as a neuroendocrine-derived colorectal cancer cell population goes along with
the known correlation of neuroendocrine neoplasms with NMYC derangement in prostate cancer.
As NMYC was shown to drive transformation of human prostate epithelial cells to prostate AC and
neuroendocrine prostate cancer [90], BKZ-3 may present a lineage plastic AC-derived colorectal cancer
cell line with a subpopulation of cells with potential stem-like characteristics and the potential to gain
neuroendocrine features. Even though a copy number gain was not detected for MYC, it was also
expressed on protein level within BKZ-2 and BKZ-3 cells. Thus, probably playing a role in maintaining
CCSC-like phenotype, too. It was demonstrated that MYC positively regulate check point inhibitor
proteins leukocyte surface antigen CD47 and PDL1 via direct binding to their encoding gene promoters
suppressing both the innate and the adaptive immune response while favoring tumor growth [91].
Further, immune checkpoint ligand PDL1 is upregulated in EMT-activated human breast cancer
cells [92] and was shown to be more highly expressed in metastatic CRC than in primary CRC [93],
suggesting its correlation with stem cell characteristics. Intriguingly, EMT and immune checkpoint
proteins maybe related to each other as EGFR activation induces EMT and PDL1 expression in cancer.
Moreover, MYC is required for EGFR-mediated PDL1 upregulation but not EMT [94]. Further, in vitro
experiments on CRC-derived tumor cell lines provided evidence that PDL2 is involved in tumor
cell invasion [95]. Giving these facts, the higher level of EMT genes, SLUG protein and immune
checkpoint ligands of BKZ-2 are probably associated with each other and may reflect a more invasive
and aggressive phenotype of the isolated neuroendocrine-derived colorectal cancer cell line BKZ-2
in comparison to BKZ-3 cells. Accordingly, the difference in PDL1 expression was also detected in
parental tumor tissue of the two cell lines with 2% of PDL1 positive vital tumor cells shown in BKZ-2
originating tissue and 0% in BKZ-3, respectively. Further analysis on CPS displayed a value of 2% for
parental tumor tissue of BKZ-2 and a CPS of 3 for tissue donating BKZ-3 cells. Thus, a slight correlation
between higher PDL1 expression in tumor cells and less PDL1 positive immune cell infiltration may
be assumed.
MYC/NMYC inhibition decreases the survival rates of both BKZ-2 and BKZ-3 cells. However,
survival rate was significantly higher for BKZ-3 cells, further reflecting a protective mechanism
against MYC/NMYC inhibitory molecules or rather a more MYC/NMYC independent growth of BKZ-3.
Moreover, BKZ-2 and BKZ-3 seem to be more resistant to KJ-Pyr-9 in comparison to HT-29 and HCT-116,
with BKZ-3 even revealing higher survival after 10 µM KJ-Pyr-9 treatment. This may be due to lower
expression levels of the CSC-markers CD133 and CD44 in HT-29 and HCT-116, which stands in line
with a study of Zhang and coworkers demonstrating a CD133 high expressing subpopulation of HT-29
cells paralleled by higher levels of MYC. Further, MYC silencing led to higher chemo sensitivity [18].
The KJ-Pyr-9 inhibitor used here as a small molecule antagonist of the protein–protein interaction of
MYC and NMYC with myc-associated factor X (MAX) was reported to inhibit dimerization of these two
molecules. Reduced survival rates were demonstrated subsequent to KJ-Pyr-9-treatment in vitro on
various tumor cell lines with concentrations of 5 to 20 µM as well as in vivo in a human to mouse tumor
xenograft model with a dosage of 10 mg/kg body weight [96], which was here presented for BKZ-2 and
BKZ-3, too. Moreover, KJ-Pyr-9-treatment led to high percentages of apoptotic cells, revealing that its
influence on survival is based on apoptosis. Interestingly, BKZ-2 cells showed significantly higher
sensitivity in comparison to BKZ-3 when treated with 10 µM. Even though BKZ-3 was less sensitive for
MYC/NMYC inhibition in comparison to BKZ-2, both colorectal cancer cell lines revealed significant
reductions of survival rates due to induced apoptosis upon MYC/NMYC inhibition. Consequently,
the usage of inhibitors of the protein–protein interaction of MYC and NMYC with MAX is a possible
treatment strategy for both neuroendocrine- and AC-derived colorectal cancer cell lines that harbor a
subpopulation with potential stem-like properties.
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4. Materials and Methods
4.1. Patients Clinical Characterisation and Oncological Treatment
Patient 1 (donor of BKZ-2 cell line) was a 79-year-old Caucasian male when admitted to the
emergency room of the Protestant Hospital of Bethel Foundation (Bielefeld, Germany) with abdominal
pain and clinical signs of an obstructive ileus. Computerized tomography (CT)-scan revealed a
malignant tumorous lesion of the upper third of the rectum with consecutive massive dilated upstream
colon (Figure 1A). Flexible rectal endoscopy confirmed a luminal subtotally occluding neoplastic lesion
(Figure 1B). Following the introduction of a self-expanding metallic endo-prosthetic stent, a passage
was reestablished (Figure 1C). Staging revealed multiple synchronic hepatic metastases of all segments
(Figure 1D). Patient 1 was scheduled for robotic deep rectal resection with primary, circular stapler
performed descendo-rectostomy. Following national guidelines and the recommendation of the local
oncological board, a systemic chemotherapy with carboplatin and Etoposid was initiated and further
switched to cisplatin and Etoposid due to hepatic progress. Patient 2 (donor of BKZ-3 cell line) was
a 64 year old Caucasian male when admitted to the emergency room of the Protestant Hospital of
Bethel Foundation (Bielefeld, Germany) with signs of sub-total ileus, abdominal crampy pain and a
history of recurring nausea and vomitus paralleled by weight loss of 15 kg in the last three months
prior admission. The patient presented a bloated abdomen without peritonism and scarce peristaltic of
the bowel. CT-scan revealed a mass of the splenic flexure of the left colon suspicious for malignancy
with distension of the pre-stenotic bowel (Figure 1E). Staging revealed no evidence of extra colonic
malignant lesions. The patient was urgently scheduled for an open left hemicolectomy with worsening
signs of mechanical bowel obstruction.
Isolation of genomic DNA of parental tumor tissue for BRAF mutation analysis was performed
using automatically DNA-extraction with Maxwell® RSC DNA FFPE Kit and the Maxwell® RSC
instrument (Promega, Walldorf, Germany) according to the manufacturers guidelines in the Institute
of Pathology KRH Hospital Nordstadt (Hannover, Germany). Sequencing of isolated genomic DNA
of parental tissue and genomic DNA of isolated cell lines (as described below) was performed using
DTCS Quick Start Kit (Beckman Coulter Life Sciences, Indianapolis, IN, USA) and GenomeLab GeXP™
Genetic Analysis System (Beckman Coulter Life Sciences) according to the manufacturers guidelines.
Informed consent according to local and international guidelines was signed by both patients.
All further experimental procedures were ethically approved (Ethics committee Münster, Germany,
2017-522-f-S).
4.2. Colorectal Cancer Cell Line Establishment and Cell Culture
To obtain primary tumor material for cell culture, a cubic sample measuring 5 mm was collected
from each tumor type. The sample was transferred to ice-cold Dulbecco’s Phosphate Buffered
Saline (PBS; Sigma Aldrich, Munich, Germany) supplemented with antibiotics penicillin/streptomycin
(500 µg/mL; Sigma Aldrich), gentamicin (100 µg/mL; Ratiopharm, Ulm, Germany) and metronidazole
(5 µg/mL; B.Braun, Melsungen, Germany), as well as the antimycotic amphotericin B (12.5 µg/mL;
Sigma Aldrich) to control colic microbiom contamination. For the isolation of the cells, the specimen
was washed ten times with ice-cold PBS, mechanically disintegrated in 2–5 mm pieces followed by
enzymatical digestion with collagenase for 2 h at 37 ◦C as described previously [63]. One half of the
minced tissue was used to cultivate spheres in Dulbecco’s Modified Eagle’s medium/Ham’s F-12 (Sigma
Aldrich) with the addition of 2 mM L-Glutamin (Sigma Aldrich), penicillin/streptomycin (100 µg/mL),
gentamicin (20 µg/mL), metronidazole (1 µg/mL), amphotericin B (2.5 µg/mL), EGF (20 ng/mL; Miltenyi
Biotec, Bergisch Gladbach, Germany), FGF-2 (40 ng/mL; Miltenyi Biotec) and B27 supplement (Gibco,
Thermo Fisher Scientific, Bremen, Germany) in low adhesion T25 tissue culture flasks. The other half
of the tissue was used to grow adherent cells, where the cells were cultivated on gelatin from bovine
skin (type B; Sigma Aldrich) coated culture dishes in the medium described above supplemented with
10% FCS (Sigma Aldrich).
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Colon adenocarcinoma cell line HT-29 (DSMZ-German Collection of Microorganisms and
Cell Cultures, Braunschweig, Germany) and colon carcinoma cell line HCT-116 (DSMZ-German
Collection of Microorganisms and Cell Cultures) were maintained in McCoy’s 5A medium (Sigma
Aldrich) with 10% FCS, 2 mM L-Glutamin, and penicillin/streptomycin (100 µg/mL). Adult HDF
(Genlantis, San Diego, CA, USA) were a kind gift from Dr. Isabel Faust, Institute for Laboratory
and Transfusion Medicine, Heart and Diabetes Centre NRW (Bad Oeynhausen, Germany) and were
cultured in Dulbecco’s Modified Eagle’s Medium-high glucose (Sigma Aldrich) with 10% FCS, 2 mM
L-Glutamin, and penicillin/streptomycin (100 µg/mL). All cells were cultured at 37 ◦C and 5% CO2 in a
humidified incubator.
Population doubling times were determined using the OranguTM Cell Counting Solution and were
performed at least six times per cell population according to the manufacturers guidelines. For this
1000, 2500, 5000, 7500, and 10,000 cells per 100 µL CSC medium containing 10% FCS were seeded in a
96 well and used as a standard curve. To calculate the population doubling time 3000 cells per 100 µL
CSC medium containing 10% FCS were seeded in a 96 well and cultured for 72 h, followed by the
measurement of cell viability and quantification of cell count using the appropriate standard curve.
Growth rates and population doubling times were determined by the following equations:
growth rate =
ln (xt) − ln (x0)
t− t0
(1)
population doubling time =
ln (2)
growth rate
(2)
4.3. Immunocytochemistry and Immunohistochemistry
For immunocytochemical cell staining, BKZ-2, BKZ-3, HT-29, HCT-116, and HDF were pre-cultured
as an explant culture as described above. After harvesting, 1.5 × 104 cells per 500 µL CSC medium
supplemented with 10% FCS were planted on top of etched cover slips. After 2–3 days of cultivation, cells
were fixed with 4% phosphate-buffered paraformaldehyde (lab-made) for 15 min at room temperature
(RT) followed by three washing steps with 1 × PBS. Cells were blocked and permeabilized using 0.02%
Triton-X 100 (Sigma Aldrich) with 5% appropriate serum (Dianova, Hamburg, Germany) or 1% bovine
serum albumin (Sigma-Aldrich) for 30 min at RT. Afterwards, cells were incubated with primary
antibodies for 1 h at RT. Antibodies used were anti-CD44 (1:400; 156-3C11; Cell Signaling, Frankfurt
am Main, Germany), anti-CD133 (1:100; NB120-16518; NovusBio, Bio-Techne, Wiesbaden-Nordenstadt,
Germany), anti-Nestin (1:200; MAB5326; Millipore, Merck, Darmstadt, Germany), anti-Synaptophysin
(1:250; MAB5258;Abcam, Berlin, Germany), anti-SLUG (1:100; C19G7; Cell Signaling), anti-S100
(1:400; Z 0311; DAKO, Agilent, Santa Clara, CA, USA), anti-Dopamine (1:100; AB1225; Millipore,
Merck), anti-vGLUT2 (1:50; MAB5504; Millipore, Merck), anti-TH (1:50; H-196; Santa Cruz, Heidelberg,
Germany), anti-Cleaved Caspase-3 (1:400; Asp175/5A1E; Cell Signaling), anti-MYC (10 µg/mL; Y69;
Abcam) and anti-NMYC (2,5 µg/mL; NCM II 100; Abcam). Secondary fluorochrome-conjugated
antibodies (1:300; goat anti-mouse Alexa 555, goat anti-rabbit Alexa 555, goat anti-mouse Alexa
488; Life Technologies, Thermo Fisher Scientific) were incubated for 1 h at RT in the dark. Nuclear
counterstaining was performed with 4′,6-diamidino-2-phenylindole (DAPI; 1 µg/mL; Sigma Aldrich)
for 10 min at RT. Fluorescence imaging was performed using a confocal laser scanning microscope
(LSM 780; Carl Zeiss, Jena, Germany) and analyzed using ZEN software from the same provider or Fiji
ImageJ [97]. For the quantification of immunofluorescence stainings, at least five images per condition
were analyzed. Percentages of SLUG and Synaptophysin high and low cells were quantified by the
mean of the nuclear fluorescence intensity, with cells showing a nuclear mean fluorescence intensity
over 15,000 clustered as SLUG and Synaptophysin high. CD133 and CD44 high, medium and low
cells were determined by 10 randomly applied measurements for fluorescence intensity on at least five
images per cell population. HDF were used as negative control and their background fluorescence was
subtracted from each measurement. Cells were classified as CD133 high: ≥ 10,000, CD133 medium:
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< 10,000 ≥ 5000 and CD133 low: < 5000 ≥ 0. For CD44 expression, cells were classified in CD44 high:
≥ 2000, CD44 medium: < 2000 ≥ 1000 and CD44 low: < 1000 ≥ 0.
All immunohistochemical stainings, except for the staining for MYC and NMYC, were performed
in the Institute of Pathology of KRH Hospital Nordstadt (Hannover, Germany) using the automated
immunohistochemistry and in situ hybridization platform Dako Omnis (DAKO, Agilent) according to
the manufacturer’s instructions. Antibodies used were: Anti-CD56 (123C3; DAKO, Agilent), anti-CK20
(Ks20.8; DAKO, Agilent), anti-Ki67 (MIB-1; DAKO, Agilent), anti-Synaptophysin (DAK-SYNAP;
DAKO, Agilent), anti-CDX2 (DAK-CDX2; DAKO, Agilent), anti-panCK (AE1/AE3; DAKO, Agilent),
anti-PDL1 (22C3; DAKO, Agilent), anti-CK7 (OV-TL 12/30; DAKO, Agilent) and anti-SATB2 (EP281;
Cell Marque, Rocklin, CA, USA). For visualization the EnVision FLEX, High pH (DAKO, Agilent)
visualization system was used according to the manufacturers guidelines. Each scoring pathologist
had specific training for the specific antibody and particular indication for testing as appropriate.
Analysis of the expression of the immune checkpoint ligand PDL1 was done according to international
standards [98].
TPS =
PDL1 positive vital tumor cells
PDL1 positive + negative vital tumor cells
(3)
CPS =
PDL1 positive vital tumor cells + lymphocytes + macrophages
PDL1 positive + negative vital tumor cells
∗ 100 (4)
IC =
PDL1 positive lymphocytes + macrophages + dendritic cells + granulocytes
tumor area
(5)
IC is given as a score with the following values: 0 = 0–<1%, 1 = ≥1%–<5%, 2 = 5%–<10%,
3 = ≥10%. For immunocytochemical staining of MYC and NMYC paraffin-embedded sections were
deparaffinized and rehydrated. For this, sections were washed two times for 10 min in xylol followed
by 10 min 100% ethanol. Afterwards, sections were rehydrated by 5 min washes in 90% ethanol,
followed by 80% ethanol and 70% ethanol. Epitope retrieval was performed by boiling the slides within
0.01 M citrate buffer, pH 6.0 (lab made) for 20 min. After cool down for at least 30 min at RT slides
were washed two times with 0.02% Triton-X 100. Afterwards, slides were blocked and permeabilized
using 0.02%Triton-X 100 with 10% appropriate serum (Dianova) and 1% bovine serum albumin for
2 h at RT. Anti-MYC (5 µg/mL; Y69; Abcam) and anti-NMYC (5 µg/mL; NCM II 100; Abcam) first
antibodies were diluted in blocking solution and incubated over night at 4 ◦C. After three washing
steps in PBS, secondary fluorochrome-conjugated antibodies (1:300; goat anti-mouse Alexa 555, goat
anti-rabbit Alexa 555; Life Technologies, Thermo Fisher Scientific) were applied and incubated for 1 h
at RT in the dark. Nuclear counterstaining was performed with DAPI (1 µg/mL) for 10 min at RT and
fluorescence imaging was performed using a confocal laser scanning microscope (LSM 780; Carl Zeiss)
and analyzed using Fiji ImageJ.
4.4. Sphere-Formation and ATRA-Treatments
To analyze the sphere-formation capacity of BKZ-2 and BKZ-3, cells were cultured in low adhesion
culture plates in CSC medium without FCS with different concentrations of heparin. Cells were
seeded in triplicates at 1 × 105 cells per 1000 µL CSC medium. Heparin (Sigma Aldrich) was added in
concentrations of 3 µg/mL, 4 µg/mL, 5 µg/mL or 0 µg/mL as a control. Cells were cultured for seven
days in a humidified cell incubator at 37 ◦C and 5% CO2. The size of the spheres was quantified for
each treatment condition at day 2, day 4, and day 7 after initial cell seeding. Therefore, five randomized
images of each well were taken, and every sphere was measured in length and width using Fiji ImageJ.
Then, the diameter of each sphere as mean of length and width was calculated. For the comparison of
sphere formation capacity of BKZ-2, BKZ-3 with HT-29 and HCT-116 and for sphere-formation under
the treatment of different concentrations of ATRA (Sigma Aldrich), cells were seeded at 5000 cells per
200 µL CSC medium containing 4 µg/ml heparin in a low adhesion 96 well-plate and cultured for five
days. For the treatment, medium was supplemented with 1 µM ATRA, 5 µM ATRA, 10 µM ATRA or
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dimethylsulfoxide (DMSO) as a control in triplicates for each treatment condition. For quantification,
two representative images of each well were taken and every sphere was measured in length and
width using Fiji ImageJ, with the mean of both representing the diameter of each sphere. Volume of
spheres was determined using the formula:
V =
4
3
∗π ∗ (
sphere diameter
2
)
2
(6)
The number of spheres was calculated by counting each sphere of all six representative images
for each condition. For total cell mass calculation, mean of sphere volume was multiplied with the
mean of sphere number. According to Weiswald and colleagues, spheres with a diameter of ≥ 20 µm
were considered for further evaluation [17]. For the analysis of the influence of ATRA on BKZ-2
and BKZ-3 in monolayer, 3000 cells per 100 µL CSC medium containing 10% FCS were seeded in a
0.1% gelatin coated 96 well-plate. Additionally, 1000, 2500, 5000, 7500, and 10,000 cells per 100 µL
medium were seeded in a 96 well for a standard curve. After adherence of the cells, cell viability was
measured for the standard curve and ATRA was applied as described above. After 5 days of treatment,
cell viability was measured and cell count was quantified using the standard curve. Each treatment
condition was performed in triplicates. For the immunocytochemical staining of cleaved caspase 3 after
ATRA-treatment, 1.5 × 104 cells per 500 µL CSC medium containing 10% FCS were seeded in a 24 well
on top of etched cover slips. After adherence, cells were treated with different ATRA concentrations as
well as DMSO as control for five days. Afterwards, cleaved caspase 3 immunocytochemical staining
was performed as described above.
4.5. Real-Time PCR
RNA isolation of cultivated cell populations was done using the NucleoSpin® RNA Plus
kit (Machery-Nagel, Düren, Germany) according to the manufacturers instruction. Quality and
concentration of RNA were assessed via Nanodrop ultraviolet spectrophotometry. Copy DNA (cDNA)
synthesis was performed using 1 µg of RNA and the First Strand cDNA Synthesis Kit (Thermo Fisher
Scientific). For the synthesis, random hexamer primers were used. qPCR were performed in triplicates
using 2 × qPCR SyGreen Mix (PCR Biosystems, London, UK), according to the manufacturer’s
instructions, and assayed with the Eco48 (PCRmax, Stone, Staffordshire, UK). Used primers (Sigma
Aldrich) are listed in Table 1. Isolation of the genomic DNA for the analysis of gene copy number of
NMYC and MYC was done using QUIamp® DNA Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s guidelines. Quantification of gene copy number was performed in triplicates
using Platinum SYBR Green qPCR Super-Mix UDG (Invitrogen, Thermo Fisher Scientific), according
to the manufacturers guidelines, and assayed with a Rotor Gene 6000 (Qiagen). Each gene assay
included: (1) a no-template control, (2) 10 ng of calibrator human genomic DNA of MSCs (Lonza,
Basel, Switzerland), and (3) 10 ng of tumor DNA. Haploid copy number was determined according to
De Preter et al. [99].
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Table 1. Primer sequences for quantitative polymerase chain reaction.
Target Sequence 5′-3′
CD44 antigen (CD44) CTACAAGCACAATCCAGGCAA
Rev-CD44 GCATTGGATGGCTGGTATGA
Programed death ligand 1 (PDL1) CCCAGTTCTGCGCAGCTT
Rev-PDL1 ACCGTGACAGTAAATGCGTTC
Programed death ligand 2 (PDL2) TCCAACTTGGCTGCTTCACA
Rev-PDL2 CCACAGGTTCAGATAGCACTGT
Prominin-1 (CD133) AACAGTTTGCCCCCAGGAAA
Rev-CD133 GAAGGACTCGTTGCTGGTGA
Epithelial cell adhesion molecule (EPCAM) GCTGGCCGTAAACTGCTTTG
Rev-EPCAM ACATTTGGCAGCCAGCTTTG
N-myc proto-oncogene (NMYC) (genomic) CGCAAAAGCCACCTCTCATTA
Rev-NMYC (genomic) TCCAGCAGATGCCACATAAGG
Octamer-binding transcription factor 4 (OCT4) CGAAAGAGAAAGCGAACCAG
Rev-OCT4 GCCGGTTACAGAACCACACT
Myc proto-oncogene (MYC) (genomic) AAAAGTGGGCGGCTGGATAC
Rev-MYC (genomic) AGGGATGGGAGGAAACGCTA
SRY-box transcription factor 2 (SOX2) GGCACTTTGCACTGGAACTT
Rev-SOX2 AGGCTGCTGGTTTTCCACTA
Twist family bHLH transcription factor 1 (TWIST) GTCCGCAGTCTTACGAGGAG
Rev-TWIST CCAGCTTGAGGGTCTGAATC
Snail family transcriptional repressor 1 (SNAIL) CCCAATCGGAAGCCTAACTA
Rev-SNAIL GGACAGAGTCCCAGATGAGC
Snail family transcriptional repressor 2 (SLUG) TCGGACCCACACATTACCTT
Rev-SLUG TTGGAGCAGTTTTTGCACTG
Actin beta TCCCTGGAGAAGAGCTACGA
Rev-Actin beta AGCACTGTGTTGGCGTACAG
Eukaryotic translation elongation factor 2 (EEF2) AGGTCGGTTCTACGCCTTTG
Rev-EEF2 TTCCCACAAGGCACATCCTC
Syndecan 4 (genomic) CAGGGTCTGGGAGCCAAGT
Rev-Syndecan 4 (genomic) GCACAGTGCTGGACATTGACA
Glyceraldehyde-3-phosphate dehydrogenase (genomic) AGACTGGCTCTTAAAAAGTGCAGG
Rev-Glyceraldehyde-3-phosphate dehydrogenase (genomic) TGCTGTAGCCAAATTCGTTGTC
4.6. MYC Inhibitor Treatment
To analyze the influence of the proto-oncogenes MYC and NMYC, cells were treated with different
concentrations of the MYC and NMYC inhibitor KJ-Pyr-9 (Merck) and cell viability assays using
OranguTM were performed in triplicates according to the manufacturers guidelines. For this, cells were
seeded in 0.1% gelatin coated 96 well-plates in the amount of 1000, 2500, 5000, 7500 and 10,000 cells per
100 µL CSC medium containing 10% FCS for a standard curve and in the amount of 3000 cells per 100 µL
CSC medium containing 10% FCS for the treatment. After adherence of the cells, cell viability was
measured for the standard curve and treatment was started applying KJ-Pyr-9 in the concentrations of
10 µM, 20 µM, 40 µM, and 60 µM, as well as DMSO as control to the CSC medium supplemented with
10% FCS. After 5 days of treatment, cell viability was measured, and cell count was quantified using the
standard curve. Survival rate was calculated by normalizing each cell count to the mean of controls for
BKZ-2 and BKZ-3. For the immunocytochemical staining of cleaved caspase 3 after KJ-Pyr-9-treatment,
1.5 × 104 cells per 500 µL CSC medium containing 10% FCS were seeded in a 24 well on top of etched
cover slips. After adherence, cells were treated with 10 µM, 20 µM, 40 µM or 60 µM of KJ-Pyr-9 or
DMSO as a control for five days. Afterwards, cleaved caspase 3 immunocytochemical staining was
performed as described above.
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4.7. Flow Cytometry
To determine the ALDH-activity, BKZ-2 and BKZ-3 were pre-cultured as an explant culture as
described above. After harvesting, using trypsin, cells were analyzed with the ALDEFLUOR™ Kit
(STEMCELL Technologies Inc., Vancouver, BC, Canada) according to the manufacturer’s instructions
by flow cytometry on a Gallios flow-cytometer (Beckman Coulter Life Sciences). Dead cells were
excluded by Propidium Iodide (Sigma Aldrich) co-staining and spectral overlap was compensated
using samples of the K562 cell line (DSMZ-German Collection of Microorganisms and Cell Cultures),
which also served as positive control. BKZ-2 and BKZ-3 cells were analyzed in parallel to yield
comparable results.
4.8. Statistical Analysis
Data were raised at least in triplicates and statistically analyzed by using Prism V5.01 software
(GraphPad Software, Inc., San Diego, CA, USA). Test for normality was performed by use of D’Agnostino
& Pearson omnibus normality test. Student’s t-test, non-parametric Kruskal–Wallis analysis of variance
(ANOVA) and Dunn’s Multiple Comparison post-hoc test or non-parametric Mann–Whitney-test
were performed to assess differences between multiple groups. A significance value of p ≤ 0.05 was
considered as statistically significant. The data are presented as the means ± standard error of the
mean (SEM).
5. Conclusions
In summary, we isolated the two novel colorectal cancer cell lines BKZ-2 and BKZ-3, originating
from a rare rectal neuroendocrine carcinoma and a colorectal AC, respectively, both containing a
subpopulation with potential stem-like properties. Thus, BKZ-2 and BKZ-3 represent excellent new
in vitro models to study colorectal cancer in cellular systems. Higher expression of CD133 and CD44 of
both cell populations and a higher number of formed spheres in comparison to well-established colon
carcinoma cell lines HT-29 and HCT-116 validated the existence of a subpopulation with potential
stem cell-like phenotype. Moreover, initial characterization revealed a gene copy number gain of
the proto-oncogene NMYC for both cell lines. Indirect inhibition of MYC/NMYC activity with ATRA
led to decreased sphere volume and total cell mass for BKZ-2, although not for BKZ-3, which is
probably caused by its effect on proliferation. Inhibition of the protein–protein interaction of MYC
and NMYC with MAX utilizing KJ-Pyr-9 exhibited a significant reduction in the survival rate of both
cell lines by the induction of apoptosis. Consequently, the blockage of these interactions may serve
as a possible treatment strategy for colorectal cancer cell lines with increased NMYC copy number.
However, differences in phenotype and the modulation of proliferation subsequent to ATRA-treatment,
respectively, underline the complexity of signaling pathways involved in tumorigenesis and CSC
maintenance of the different subclasses of colorectal cancer cells warranting further studies on this
relevant topic.
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